Study links new anticoagulants to higher GI bleeding risk

07/3/2013 | Healio

The new oral anticoagulants dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban may be linked to a higher risk of gastrointestinal bleeding compared with standard treatment, according to a study in the journal Gastroenterology. Researchers reviewed information from 43 randomized trials and concluded that more trials are needed to clarify the link.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA